SOURCE: Caribbean International Holdings, Inc.

Mark Farber MD, PhD, MS Received Degrees From Brown University and SUNY; During His Time at Harvard Medical School He Developed Bioreactor Designs for Stem Cell Based Tissue Engineered Heart Valves

SARASOTA, FL--(Marketwired - September 04, 2014) - Caribbean International Holdings (PINKSHEETS: CIHN) through its subsidiary, Regenerative BioScience, Inc. ("RBS"), announced today that on August 27, 2014, a private investment group, J3 Financial, has acquired a controlling interest in the Company. Former CEO and former controlling shareholder, Steven Swank has resigned as of that same date; and effective as of August 28, 2014, the Company has appointed Mark Farber MD, PhD, MS as the new CEO of CIHN.

A spokesperson for J3 stated that: "We had been tracking CIHN for some time and found its business model very attractive. We feel that this is a company that is ready to emerge and being able to acquire the talents and services of someone like Dr. Farber, will help us establish a sound foundation for future growth. We feel very lucky to have him onboard."

The Company also said that it intends to identify, recruit and hire additional industry professionals within the emerging stem cell industry as it builds the infrastructure to support a solid but steady growth. It will also be adding administrative and other veteran executives in key positions.

The Company spokesperson also said that the Company feels it is important in today's market to keep its shareholders fully abreast of ongoing events and or news and it plans on keeping the market up to date in order to remain fully transparent with the Company's current and/or potential future shareholders and the market at large. In that light, management of the Company will shortly be releasing a Shareholder Update and other pertinent information as it becomes available.

Below is a brief background and bio on the new CEO of CIHN, Mark Farber, MD, PhD, MS.

Dr. Mark Farber received his undergraduate degree in Chemical Engineering from Brown University in Providence, RI in 2001, followed by a Masters in Science in Engineering from Brown University in 2003.He received his MD/PhD combined degree from SUNY Downstate Medical Center in Brooklyn, NY in 2013.His PhD project titled "Simultaneous functional diffuse optical tomography and EEG in freely moving rats" involved developing an emerging non-invasive optical imaging technology to investigate brain blood flow in anesthetized, freely foraging, and sleeping rats.

During the development of the diffuse optical tomography optical imager, Dr. Farber's research generated over $7 million in grants, including $130,000 from the competitive NIH Ruth Kirschstein National Research Service Award for MD/PhD students from the NIH/NINDS.The technology behind his PhD project for rat brain imaging was sold for over $750,000, and with the assistance of Dr. Farber his technology has been adapted for use in macaque research, clinical research, and the development of brain-machine interfaces.

Prior to completing his education in medicine and engineering, Dr. Farber spent three years working in developing stem cell bioreactors for use in research and tissue engineering.After completing his MS in Engineering, Dr. Farber briefly worked at ViaCell Inc. where he developed bioreactors to maximize stem cell yields from umbilical cord blood cultures.He then moved on to Harvard Medical School, where he worked in the Cardiovascular Pathology department and participated in research projects involving atherosclerosis, heart valve disease, embryology, and tissue engineering.During this time he initiated investigations into novel computerized methods of tissue collagen detection and quantification and developed bioreactor designs for stem cell based tissue engineered heart valves.

Read the rest here:
Caribbean International Holdings (CIHN) Announces Change in Control; Seasoned Veteran in Stem Cell Industry Appointed ...